Skip to main content
Premium Trial:

Request an Annual Quote

Cytox: Ian Gilham

Cytox has appointed Ian Gilham its chairman of the board. He was CEO of Axis-Shield until Alere acquired the company in 2011. He also held positions at Amersham International, Abbott Laboratories, and GlaxoSmithKline. Gilham is currently non-executive chairman of Horizon Discovery, Genedrive, and Biosurfit and previously was chairman of Multiplicom and Elucigene. Oxford, UK-based Cytox develops noninvasive risk assessment and patient stratification tools for Alzheimer's disease and dementia. 

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.